StockWatch
·

Kwality Pharmaceuticals Ltd Q4 FY26 Results

KPLQ4 FY26 Results
Filing
MetricValue (₹ Cr)Q3 FY26Q4 FY25
Revenue156.8227.0%35.6%
Total Income157.8827.4%35.6%
Expenditure126.2325.2%29.7%
PBT31.6541.6%65.8%
Net Profit25.2958.0%74.4%
OPM24.70%1.11pp2.31pp
NPM16.02%3.11pp3.57pp
EPS24.3757.9%74.5%
View full financials

Kwality Pharma FY26 Revenue Up ~36% YoY to ₹503 Cr

19 May 2026 · 19 May, 11:52 am

Summary

Kwality Pharmaceuticals Ltd (KPL) delivered a landmark financial performance in FY26, achieving its highest ever quarterly and annual revenues, underpinned by strong execution. For Q4 FY26, KPL reported its strongest-ever quarterly topline of ₹157.11 crore, representing a robust year-on-year growth of 35.8%. The full year FY26 closed with consolidated revenues of ₹503 crore, a significant growth of approximately 36% YoY, fulfilling a strategic revenue commitment. The company also witnessed meaningful margin expansion, with EBITDA margins improving to 24% and PAT margins expanding to 13.4%, as Profit After Tax (PAT) for FY26 grew by approximately 69% to ₹267.34 crore. Operationally, FY26 was a defining year for KPL’s global regulatory and business development initiatives, including a credit rating upgrade and strategic investments in product development.

Key Highlights

  1. 1

    Kwality Pharmaceuticals Ltd (KPL) achieved its strongest-ever quarterly revenue of ₹157.11 crore for Q4 FY26, representing a robust year-on-year growth of 35.8%.

  2. 2

    Consolidated revenues for the full year FY26 reached ₹503 crore, marking a significant growth of approximately 36% year-on-year compared to ₹370 crore in FY25.

  3. 3

    Profit After Tax (PAT) for FY26 surged by approximately 69% year-on-year to ₹267.34 crore, materially outpacing revenue growth compared to ₹39.80 crore in FY25.

  4. 4

    EBITDA margins improved by approximately 200 basis points to 24% in FY26, up from 22% in FY25, driven by an improved product mix and operating leverage benefits.

  5. 5

    PAT margins expanded by nearly 260 basis points, improving from 10.8% in FY25 to 13.4% in FY26, reflecting enhanced operational efficiencies and tighter cost controls.

  6. 6

    ICRA upgraded KPL's credit rating to BBB+ from B+ during the quarter, indicating a strengthened financial profile.

  7. 7

    KPL initiated a large-scale Bioequivalence program covering more than 40 Oral Solid Dosage molecules to support global filings and maximize utilization of its OSD capacities.

Informational and educational content only. Not investment advice.